Global Immunotherapy for Neuroblastoma Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
The global Immunotherapy for Neuroblastoma market size is projected to grow from US$ 44 million in 2022 to US$ 61 million in 2029; it is expected to grow at a CAGR of 4.8% from 2023 to 2029.
United States market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Immunotherapy for Neuroblastoma players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
LPI (LP Information)' newest research report, the “Immunotherapy for Neuroblastoma Industry Forecast” looks at past sales and reviews total world Immunotherapy for Neuroblastoma sales in 2022, providing a comprehensive analysis by region and market sector of projected Immunotherapy for Neuroblastoma sales for 2023 through 2029. With Immunotherapy for Neuroblastoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immunotherapy for Neuroblastoma industry.
This Insight Report provides a comprehensive analysis of the global Immunotherapy for Neuroblastoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immunotherapy for Neuroblastoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immunotherapy for Neuroblastoma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immunotherapy for Neuroblastoma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immunotherapy for Neuroblastoma.
This report presents a comprehensive overview, market shares, and growth opportunities of Immunotherapy for Neuroblastoma market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
The global Immunotherapy for Neuroblastoma market size is projected to grow from US$ 44 million in 2022 to US$ 61 million in 2029; it is expected to grow at a CAGR of 4.8% from 2023 to 2029.
United States market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
China market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Europe market for Immunotherapy for Neuroblastoma is estimated to increase from US$ million in 2022 to US$ million by 2029, at a CAGR of % from 2023 through 2029.
Global key Immunotherapy for Neuroblastoma players cover United Therapeutics, Y-mAbs Therapeutics, EUSA Pharma, ANI Pharmaceuticals, Baxter Healthcare, Ingenus Pharmaceuticals, Pfizer, Hikma Pharmaceuticals and Teva Pharmaceuticals, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2022.
Neuroblastoma (NB) is the most common cancer in childhood and infancy. Most children with neuroblastoma are diagnosed before age 5 and symptoms can range from a painless bump in the abdomen to fevers and limp. Neuroblastoma treatment depends on multiple factors, including the patient's age, whether the tumor has already spread beyond its initial location and the risk of the tumor growing or spreading in the future.
LPI (LP Information)' newest research report, the “Immunotherapy for Neuroblastoma Industry Forecast” looks at past sales and reviews total world Immunotherapy for Neuroblastoma sales in 2022, providing a comprehensive analysis by region and market sector of projected Immunotherapy for Neuroblastoma sales for 2023 through 2029. With Immunotherapy for Neuroblastoma sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Immunotherapy for Neuroblastoma industry.
This Insight Report provides a comprehensive analysis of the global Immunotherapy for Neuroblastoma landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Immunotherapy for Neuroblastoma portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Immunotherapy for Neuroblastoma market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Immunotherapy for Neuroblastoma and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Immunotherapy for Neuroblastoma.
This report presents a comprehensive overview, market shares, and growth opportunities of Immunotherapy for Neuroblastoma market by product type, application, key players and key regions and countries.
Market Segmentation:
Segmentation by type
- Dinutuximab
- Naxitamab
- Other
- Hospital
- Clinic
- Other
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- United Therapeutics
- Y-mAbs Therapeutics
- EUSA Pharma
- ANI Pharmaceuticals
- Baxter Healthcare
- Ingenus Pharmaceuticals
- Pfizer
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immunotherapy for Neuroblastoma Market Size 2018-2029
2.1.2 Immunotherapy for Neuroblastoma Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Immunotherapy for Neuroblastoma Segment by Type
2.2.1 Dinutuximab
2.2.2 Naxitamab
2.2.3 Other
2.3 Immunotherapy for Neuroblastoma Market Size by Type
2.3.1 Immunotherapy for Neuroblastoma Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
2.4 Immunotherapy for Neuroblastoma Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Immunotherapy for Neuroblastoma Market Size by Application
2.5.1 Immunotherapy for Neuroblastoma Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
3 IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET SIZE BY PLAYER
3.1 Immunotherapy for Neuroblastoma Market Size Market Share by Players
3.1.1 Global Immunotherapy for Neuroblastoma Revenue by Players (2018-2023)
3.1.2 Global Immunotherapy for Neuroblastoma Revenue Market Share by Players (2018-2023)
3.2 Global Immunotherapy for Neuroblastoma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IMMUNOTHERAPY FOR NEUROBLASTOMA BY REGIONS
4.1 Immunotherapy for Neuroblastoma Market Size by Regions (2018-2023)
4.2 Americas Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)
4.3 APAC Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)
4.4 Europe Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)
4.5 Middle East & Africa Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Immunotherapy for Neuroblastoma Market Size by Country (2018-2023)
5.2 Americas Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
5.3 Americas Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immunotherapy for Neuroblastoma Market Size by Region (2018-2023)
6.2 APAC Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
6.3 APAC Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Immunotherapy for Neuroblastoma by Country (2018-2023)
7.2 Europe Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
7.3 Europe Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immunotherapy for Neuroblastoma by Region (2018-2023)
8.2 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
8.3 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET FORECAST
10.1 Global Immunotherapy for Neuroblastoma Forecast by Regions (2024-2029)
10.1.1 Global Immunotherapy for Neuroblastoma Forecast by Regions (2024-2029)
10.1.2 Americas Immunotherapy for Neuroblastoma Forecast
10.1.3 APAC Immunotherapy for Neuroblastoma Forecast
10.1.4 Europe Immunotherapy for Neuroblastoma Forecast
10.1.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast
10.2 Americas Immunotherapy for Neuroblastoma Forecast by Country (2024-2029)
10.2.1 United States Immunotherapy for Neuroblastoma Market Forecast
10.2.2 Canada Immunotherapy for Neuroblastoma Market Forecast
10.2.3 Mexico Immunotherapy for Neuroblastoma Market Forecast
10.2.4 Brazil Immunotherapy for Neuroblastoma Market Forecast
10.3 APAC Immunotherapy for Neuroblastoma Forecast by Region (2024-2029)
10.3.1 China Immunotherapy for Neuroblastoma Market Forecast
10.3.2 Japan Immunotherapy for Neuroblastoma Market Forecast
10.3.3 Korea Immunotherapy for Neuroblastoma Market Forecast
10.3.4 Southeast Asia Immunotherapy for Neuroblastoma Market Forecast
10.3.5 India Immunotherapy for Neuroblastoma Market Forecast
10.3.6 Australia Immunotherapy for Neuroblastoma Market Forecast
10.4 Europe Immunotherapy for Neuroblastoma Forecast by Country (2024-2029)
10.4.1 Germany Immunotherapy for Neuroblastoma Market Forecast
10.4.2 France Immunotherapy for Neuroblastoma Market Forecast
10.4.3 UK Immunotherapy for Neuroblastoma Market Forecast
10.4.4 Italy Immunotherapy for Neuroblastoma Market Forecast
10.4.5 Russia Immunotherapy for Neuroblastoma Market Forecast
10.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast by Region (2024-2029)
10.5.1 Egypt Immunotherapy for Neuroblastoma Market Forecast
10.5.2 South Africa Immunotherapy for Neuroblastoma Market Forecast
10.5.3 Israel Immunotherapy for Neuroblastoma Market Forecast
10.5.4 Turkey Immunotherapy for Neuroblastoma Market Forecast
10.5.5 GCC Countries Immunotherapy for Neuroblastoma Market Forecast
10.6 Global Immunotherapy for Neuroblastoma Forecast by Type (2024-2029)
10.7 Global Immunotherapy for Neuroblastoma Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 United Therapeutics
11.1.1 United Therapeutics Company Information
11.1.2 United Therapeutics Immunotherapy for Neuroblastoma Product Offered
11.1.3 United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 United Therapeutics Main Business Overview
11.1.5 United Therapeutics Latest Developments
11.2 Y-mAbs Therapeutics
11.2.1 Y-mAbs Therapeutics Company Information
11.2.2 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered
11.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Y-mAbs Therapeutics Main Business Overview
11.2.5 Y-mAbs Therapeutics Latest Developments
11.3 EUSA Pharma
11.3.1 EUSA Pharma Company Information
11.3.2 EUSA Pharma Immunotherapy for Neuroblastoma Product Offered
11.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 EUSA Pharma Main Business Overview
11.3.5 EUSA Pharma Latest Developments
11.4 ANI Pharmaceuticals
11.4.1 ANI Pharmaceuticals Company Information
11.4.2 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 ANI Pharmaceuticals Main Business Overview
11.4.5 ANI Pharmaceuticals Latest Developments
11.5 Baxter Healthcare
11.5.1 Baxter Healthcare Company Information
11.5.2 Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered
11.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Baxter Healthcare Main Business Overview
11.5.5 Baxter Healthcare Latest Developments
11.6 Ingenus Pharmaceuticals
11.6.1 Ingenus Pharmaceuticals Company Information
11.6.2 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Ingenus Pharmaceuticals Main Business Overview
11.6.5 Ingenus Pharmaceuticals Latest Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Immunotherapy for Neuroblastoma Product Offered
11.7.3 Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Pfizer Main Business Overview
11.7.5 Pfizer Latest Developments
11.8 Hikma Pharmaceuticals
11.8.1 Hikma Pharmaceuticals Company Information
11.8.2 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Hikma Pharmaceuticals Main Business Overview
11.8.5 Hikma Pharmaceuticals Latest Developments
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Information
11.9.2 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Teva Pharmaceuticals Main Business Overview
11.9.5 Teva Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Immunotherapy for Neuroblastoma Market Size 2018-2029
2.1.2 Immunotherapy for Neuroblastoma Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Immunotherapy for Neuroblastoma Segment by Type
2.2.1 Dinutuximab
2.2.2 Naxitamab
2.2.3 Other
2.3 Immunotherapy for Neuroblastoma Market Size by Type
2.3.1 Immunotherapy for Neuroblastoma Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
2.4 Immunotherapy for Neuroblastoma Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.4.3 Other
2.5 Immunotherapy for Neuroblastoma Market Size by Application
2.5.1 Immunotherapy for Neuroblastoma Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
3 IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET SIZE BY PLAYER
3.1 Immunotherapy for Neuroblastoma Market Size Market Share by Players
3.1.1 Global Immunotherapy for Neuroblastoma Revenue by Players (2018-2023)
3.1.2 Global Immunotherapy for Neuroblastoma Revenue Market Share by Players (2018-2023)
3.2 Global Immunotherapy for Neuroblastoma Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 IMMUNOTHERAPY FOR NEUROBLASTOMA BY REGIONS
4.1 Immunotherapy for Neuroblastoma Market Size by Regions (2018-2023)
4.2 Americas Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)
4.3 APAC Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)
4.4 Europe Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)
4.5 Middle East & Africa Immunotherapy for Neuroblastoma Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Immunotherapy for Neuroblastoma Market Size by Country (2018-2023)
5.2 Americas Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
5.3 Americas Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Immunotherapy for Neuroblastoma Market Size by Region (2018-2023)
6.2 APAC Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
6.3 APAC Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Immunotherapy for Neuroblastoma by Country (2018-2023)
7.2 Europe Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
7.3 Europe Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Immunotherapy for Neuroblastoma by Region (2018-2023)
8.2 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2018-2023)
8.3 Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL IMMUNOTHERAPY FOR NEUROBLASTOMA MARKET FORECAST
10.1 Global Immunotherapy for Neuroblastoma Forecast by Regions (2024-2029)
10.1.1 Global Immunotherapy for Neuroblastoma Forecast by Regions (2024-2029)
10.1.2 Americas Immunotherapy for Neuroblastoma Forecast
10.1.3 APAC Immunotherapy for Neuroblastoma Forecast
10.1.4 Europe Immunotherapy for Neuroblastoma Forecast
10.1.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast
10.2 Americas Immunotherapy for Neuroblastoma Forecast by Country (2024-2029)
10.2.1 United States Immunotherapy for Neuroblastoma Market Forecast
10.2.2 Canada Immunotherapy for Neuroblastoma Market Forecast
10.2.3 Mexico Immunotherapy for Neuroblastoma Market Forecast
10.2.4 Brazil Immunotherapy for Neuroblastoma Market Forecast
10.3 APAC Immunotherapy for Neuroblastoma Forecast by Region (2024-2029)
10.3.1 China Immunotherapy for Neuroblastoma Market Forecast
10.3.2 Japan Immunotherapy for Neuroblastoma Market Forecast
10.3.3 Korea Immunotherapy for Neuroblastoma Market Forecast
10.3.4 Southeast Asia Immunotherapy for Neuroblastoma Market Forecast
10.3.5 India Immunotherapy for Neuroblastoma Market Forecast
10.3.6 Australia Immunotherapy for Neuroblastoma Market Forecast
10.4 Europe Immunotherapy for Neuroblastoma Forecast by Country (2024-2029)
10.4.1 Germany Immunotherapy for Neuroblastoma Market Forecast
10.4.2 France Immunotherapy for Neuroblastoma Market Forecast
10.4.3 UK Immunotherapy for Neuroblastoma Market Forecast
10.4.4 Italy Immunotherapy for Neuroblastoma Market Forecast
10.4.5 Russia Immunotherapy for Neuroblastoma Market Forecast
10.5 Middle East & Africa Immunotherapy for Neuroblastoma Forecast by Region (2024-2029)
10.5.1 Egypt Immunotherapy for Neuroblastoma Market Forecast
10.5.2 South Africa Immunotherapy for Neuroblastoma Market Forecast
10.5.3 Israel Immunotherapy for Neuroblastoma Market Forecast
10.5.4 Turkey Immunotherapy for Neuroblastoma Market Forecast
10.5.5 GCC Countries Immunotherapy for Neuroblastoma Market Forecast
10.6 Global Immunotherapy for Neuroblastoma Forecast by Type (2024-2029)
10.7 Global Immunotherapy for Neuroblastoma Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 United Therapeutics
11.1.1 United Therapeutics Company Information
11.1.2 United Therapeutics Immunotherapy for Neuroblastoma Product Offered
11.1.3 United Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 United Therapeutics Main Business Overview
11.1.5 United Therapeutics Latest Developments
11.2 Y-mAbs Therapeutics
11.2.1 Y-mAbs Therapeutics Company Information
11.2.2 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered
11.2.3 Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Y-mAbs Therapeutics Main Business Overview
11.2.5 Y-mAbs Therapeutics Latest Developments
11.3 EUSA Pharma
11.3.1 EUSA Pharma Company Information
11.3.2 EUSA Pharma Immunotherapy for Neuroblastoma Product Offered
11.3.3 EUSA Pharma Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 EUSA Pharma Main Business Overview
11.3.5 EUSA Pharma Latest Developments
11.4 ANI Pharmaceuticals
11.4.1 ANI Pharmaceuticals Company Information
11.4.2 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.4.3 ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 ANI Pharmaceuticals Main Business Overview
11.4.5 ANI Pharmaceuticals Latest Developments
11.5 Baxter Healthcare
11.5.1 Baxter Healthcare Company Information
11.5.2 Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered
11.5.3 Baxter Healthcare Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Baxter Healthcare Main Business Overview
11.5.5 Baxter Healthcare Latest Developments
11.6 Ingenus Pharmaceuticals
11.6.1 Ingenus Pharmaceuticals Company Information
11.6.2 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.6.3 Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Ingenus Pharmaceuticals Main Business Overview
11.6.5 Ingenus Pharmaceuticals Latest Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Immunotherapy for Neuroblastoma Product Offered
11.7.3 Pfizer Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Pfizer Main Business Overview
11.7.5 Pfizer Latest Developments
11.8 Hikma Pharmaceuticals
11.8.1 Hikma Pharmaceuticals Company Information
11.8.2 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.8.3 Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Hikma Pharmaceuticals Main Business Overview
11.8.5 Hikma Pharmaceuticals Latest Developments
11.9 Teva Pharmaceuticals
11.9.1 Teva Pharmaceuticals Company Information
11.9.2 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
11.9.3 Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Teva Pharmaceuticals Main Business Overview
11.9.5 Teva Pharmaceuticals Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Immunotherapy for Neuroblastoma Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Dinutuximab
Table 3. Major Players of Naxitamab
Table 4. Major Players of Other
Table 5. Immunotherapy for Neuroblastoma Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 6. Global Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 7. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 8. Immunotherapy for Neuroblastoma Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 9. Global Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 10. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 11. Global Immunotherapy for Neuroblastoma Revenue by Players (2018-2023) & ($ Millions)
Table 12. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player (2018-2023)
Table 13. Immunotherapy for Neuroblastoma Key Players Head office and Products Offered
Table 14. Immunotherapy for Neuroblastoma Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Immunotherapy for Neuroblastoma Market Size by Regions 2018-2023 & ($ Millions)
Table 18. Global Immunotherapy for Neuroblastoma Market Size Market Share by Regions (2018-2023)
Table 19. Global Immunotherapy for Neuroblastoma Revenue by Country/Region (2018-2023) & ($ millions)
Table 20. Global Immunotherapy for Neuroblastoma Revenue Market Share by Country/Region (2018-2023)
Table 21. Americas Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & ($ Millions)
Table 22. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Country (2018-2023)
Table 23. Americas Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 24. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 25. Americas Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 26. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 27. APAC Immunotherapy for Neuroblastoma Market Size by Region (2018-2023) & ($ Millions)
Table 28. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region (2018-2023)
Table 29. APAC Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 30. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 31. APAC Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 32. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 33. Europe Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & ($ Millions)
Table 34. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country (2018-2023)
Table 35. Europe Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 36. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 37. Europe Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 38. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 39. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Region (2018-2023) & ($ Millions)
Table 40. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Region (2018-2023)
Table 41. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 42. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 43. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 45. Key Market Drivers & Growth Opportunities of Immunotherapy for Neuroblastoma
Table 46. Key Market Challenges & Risks of Immunotherapy for Neuroblastoma
Table 47. Key Industry Trends of Immunotherapy for Neuroblastoma
Table 48. Global Immunotherapy for Neuroblastoma Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 49. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Regions (2024-2029)
Table 50. Global Immunotherapy for Neuroblastoma Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 51. Global Immunotherapy for Neuroblastoma Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 52. United Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 53. United Therapeutics Immunotherapy for Neuroblastoma Product Offered
Table 54. United Therapeutics Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 55. United Therapeutics Main Business
Table 56. United Therapeutics Latest Developments
Table 57. Y-mAbs Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 58. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered
Table 59. Y-mAbs Therapeutics Main Business
Table 60. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 61. Y-mAbs Therapeutics Latest Developments
Table 62. EUSA Pharma Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 63. EUSA Pharma Immunotherapy for Neuroblastoma Product Offered
Table 64. EUSA Pharma Main Business
Table 65. EUSA Pharma Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 66. EUSA Pharma Latest Developments
Table 67. ANI Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 68. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 69. ANI Pharmaceuticals Main Business
Table 70. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 71. ANI Pharmaceuticals Latest Developments
Table 72. Baxter Healthcare Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 73. Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered
Table 74. Baxter Healthcare Main Business
Table 75. Baxter Healthcare Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 76. Baxter Healthcare Latest Developments
Table 77. Ingenus Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 78. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 79. Ingenus Pharmaceuticals Main Business
Table 80. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 81. Ingenus Pharmaceuticals Latest Developments
Table 82. Pfizer Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 83. Pfizer Immunotherapy for Neuroblastoma Product Offered
Table 84. Pfizer Main Business
Table 85. Pfizer Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 86. Pfizer Latest Developments
Table 87. Hikma Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 88. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 89. Hikma Pharmaceuticals Main Business
Table 90. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 91. Hikma Pharmaceuticals Latest Developments
Table 92. Teva Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 93. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 94. Teva Pharmaceuticals Main Business
Table 95. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 96. Teva Pharmaceuticals Latest Developments
Table 1. Immunotherapy for Neuroblastoma Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Dinutuximab
Table 3. Major Players of Naxitamab
Table 4. Major Players of Other
Table 5. Immunotherapy for Neuroblastoma Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 6. Global Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 7. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 8. Immunotherapy for Neuroblastoma Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 9. Global Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 10. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 11. Global Immunotherapy for Neuroblastoma Revenue by Players (2018-2023) & ($ Millions)
Table 12. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player (2018-2023)
Table 13. Immunotherapy for Neuroblastoma Key Players Head office and Products Offered
Table 14. Immunotherapy for Neuroblastoma Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 15. New Products and Potential Entrants
Table 16. Mergers & Acquisitions, Expansion
Table 17. Global Immunotherapy for Neuroblastoma Market Size by Regions 2018-2023 & ($ Millions)
Table 18. Global Immunotherapy for Neuroblastoma Market Size Market Share by Regions (2018-2023)
Table 19. Global Immunotherapy for Neuroblastoma Revenue by Country/Region (2018-2023) & ($ millions)
Table 20. Global Immunotherapy for Neuroblastoma Revenue Market Share by Country/Region (2018-2023)
Table 21. Americas Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & ($ Millions)
Table 22. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Country (2018-2023)
Table 23. Americas Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 24. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 25. Americas Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 26. Americas Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 27. APAC Immunotherapy for Neuroblastoma Market Size by Region (2018-2023) & ($ Millions)
Table 28. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region (2018-2023)
Table 29. APAC Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 30. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 31. APAC Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 32. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 33. Europe Immunotherapy for Neuroblastoma Market Size by Country (2018-2023) & ($ Millions)
Table 34. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country (2018-2023)
Table 35. Europe Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 36. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 37. Europe Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 38. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 39. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Region (2018-2023) & ($ Millions)
Table 40. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Region (2018-2023)
Table 41. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Type (2018-2023) & ($ Millions)
Table 42. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Table 43. Middle East & Africa Immunotherapy for Neuroblastoma Market Size by Application (2018-2023) & ($ Millions)
Table 44. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Table 45. Key Market Drivers & Growth Opportunities of Immunotherapy for Neuroblastoma
Table 46. Key Market Challenges & Risks of Immunotherapy for Neuroblastoma
Table 47. Key Industry Trends of Immunotherapy for Neuroblastoma
Table 48. Global Immunotherapy for Neuroblastoma Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 49. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Regions (2024-2029)
Table 50. Global Immunotherapy for Neuroblastoma Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 51. Global Immunotherapy for Neuroblastoma Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 52. United Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 53. United Therapeutics Immunotherapy for Neuroblastoma Product Offered
Table 54. United Therapeutics Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 55. United Therapeutics Main Business
Table 56. United Therapeutics Latest Developments
Table 57. Y-mAbs Therapeutics Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 58. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Product Offered
Table 59. Y-mAbs Therapeutics Main Business
Table 60. Y-mAbs Therapeutics Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 61. Y-mAbs Therapeutics Latest Developments
Table 62. EUSA Pharma Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 63. EUSA Pharma Immunotherapy for Neuroblastoma Product Offered
Table 64. EUSA Pharma Main Business
Table 65. EUSA Pharma Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 66. EUSA Pharma Latest Developments
Table 67. ANI Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 68. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 69. ANI Pharmaceuticals Main Business
Table 70. ANI Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 71. ANI Pharmaceuticals Latest Developments
Table 72. Baxter Healthcare Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 73. Baxter Healthcare Immunotherapy for Neuroblastoma Product Offered
Table 74. Baxter Healthcare Main Business
Table 75. Baxter Healthcare Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 76. Baxter Healthcare Latest Developments
Table 77. Ingenus Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 78. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 79. Ingenus Pharmaceuticals Main Business
Table 80. Ingenus Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 81. Ingenus Pharmaceuticals Latest Developments
Table 82. Pfizer Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 83. Pfizer Immunotherapy for Neuroblastoma Product Offered
Table 84. Pfizer Main Business
Table 85. Pfizer Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 86. Pfizer Latest Developments
Table 87. Hikma Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 88. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 89. Hikma Pharmaceuticals Main Business
Table 90. Hikma Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 91. Hikma Pharmaceuticals Latest Developments
Table 92. Teva Pharmaceuticals Details, Company Type, Immunotherapy for Neuroblastoma Area Served and Its Competitors
Table 93. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Product Offered
Table 94. Teva Pharmaceuticals Main Business
Table 95. Teva Pharmaceuticals Immunotherapy for Neuroblastoma Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 96. Teva Pharmaceuticals Latest Developments
LIST OF FIGURES
Figure 1. Immunotherapy for Neuroblastoma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Immunotherapy for Neuroblastoma Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Immunotherapy for Neuroblastoma Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region (2022)
Figure 8. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2022
Figure 10. Immunotherapy for Neuroblastoma in Hospital
Figure 11. Global Immunotherapy for Neuroblastoma Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Immunotherapy for Neuroblastoma in Clinic
Figure 13. Global Immunotherapy for Neuroblastoma Market: Clinic (2018-2023) & ($ Millions)
Figure 14. Immunotherapy for Neuroblastoma in Other
Figure 15. Global Immunotherapy for Neuroblastoma Market: Other (2018-2023) & ($ Millions)
Figure 16. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2022
Figure 17. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player in 2022
Figure 18. Global Immunotherapy for Neuroblastoma Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Immunotherapy for Neuroblastoma Market Size 2018-2023 ($ Millions)
Figure 20. APAC Immunotherapy for Neuroblastoma Market Size 2018-2023 ($ Millions)
Figure 21. Europe Immunotherapy for Neuroblastoma Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2018-2023 ($ Millions)
Figure 23. Americas Immunotherapy for Neuroblastoma Value Market Share by Country in 2022
Figure 24. United States Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region in 2022
Figure 29. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2022
Figure 30. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2022
Figure 31. China Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country in 2022
Figure 38. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Figure 39. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Figure 40. Germany Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 54. APAC Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 55. Europe Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 57. United States Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 58. Canada Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 61. China Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 62. Japan Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 63. Korea Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 65. India Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 66. Australia Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 67. Germany Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 68. France Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 69. UK Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 70. Italy Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 71. Russia Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 72. Spain Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 75. Israel Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 78. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Immunotherapy for Neuroblastoma Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Immunotherapy for Neuroblastoma Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Immunotherapy for Neuroblastoma Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region (2022)
Figure 8. Immunotherapy for Neuroblastoma Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2022
Figure 10. Immunotherapy for Neuroblastoma in Hospital
Figure 11. Global Immunotherapy for Neuroblastoma Market: Hospital (2018-2023) & ($ Millions)
Figure 12. Immunotherapy for Neuroblastoma in Clinic
Figure 13. Global Immunotherapy for Neuroblastoma Market: Clinic (2018-2023) & ($ Millions)
Figure 14. Immunotherapy for Neuroblastoma in Other
Figure 15. Global Immunotherapy for Neuroblastoma Market: Other (2018-2023) & ($ Millions)
Figure 16. Global Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2022
Figure 17. Global Immunotherapy for Neuroblastoma Revenue Market Share by Player in 2022
Figure 18. Global Immunotherapy for Neuroblastoma Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Immunotherapy for Neuroblastoma Market Size 2018-2023 ($ Millions)
Figure 20. APAC Immunotherapy for Neuroblastoma Market Size 2018-2023 ($ Millions)
Figure 21. Europe Immunotherapy for Neuroblastoma Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2018-2023 ($ Millions)
Figure 23. Americas Immunotherapy for Neuroblastoma Value Market Share by Country in 2022
Figure 24. United States Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Region in 2022
Figure 29. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Type in 2022
Figure 30. APAC Immunotherapy for Neuroblastoma Market Size Market Share by Application in 2022
Figure 31. China Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Country in 2022
Figure 38. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Figure 39. Europe Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Figure 40. Germany Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Immunotherapy for Neuroblastoma Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Immunotherapy for Neuroblastoma Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 54. APAC Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 55. Europe Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 57. United States Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 58. Canada Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 61. China Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 62. Japan Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 63. Korea Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 65. India Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 66. Australia Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 67. Germany Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 68. France Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 69. UK Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 70. Italy Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 71. Russia Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 72. Spain Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 75. Israel Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Immunotherapy for Neuroblastoma Market Size 2024-2029 ($ Millions)
Figure 78. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Immunotherapy for Neuroblastoma Market Size Market Share Forecast by Application (2024-2029)
